PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Long-Term platelet control in rare bleeding disorder
Disease control CompletedThis phase 3 trial tested the long-term safety and effectiveness of efgartigimod, an IV drug, in 101 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants received efgartigimod infusions over 52 w…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
ITP study reveals hidden toll on brain and body
Knowledge-focused CompletedThis study looked at how chronic immune thrombocytopenia (ITP) affects thinking skills and fatigue in adults. Researchers measured brain function and inflammation using blood tests and questionnaires in 97 patients. The goal was to better understand these connections, not to test…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC